- 询价
- 辰辉创聚生物®️
- 中国
- NBL-250393
- 2026年05月19日
相关产品推荐更多 >
重组小鼠Neuropilin-2蛋白 | Recombinant Mouse Neuropilin-2, His-tag
询价
重组人SDHB蛋白 | Recombinant Human SDHB Protein, 38-280aa, His-tag
询价重组人ILKAP蛋白 | Recombinant Human ILKAP, His-tag
询价
重组人Peroxisome Proliferator Activated Receptor Alpha (PPARa)蛋白 | Recombinant Peroxisome Proliferator Activated Receptor Alpha (PPARa), 61-170aa, His-tag
询价重组人AGT蛋白 | Recombinant Human AGT Protein, 35-485aa, GST-tag
询价
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保质期：
见COA
- 库存：
大量
- 供应商：
北京辰辉创聚生物技术有限公司
- 规格：
100ug; 500ug; 1mg; Bulk
| 产品信息
品名：NebuSelect™ Recombinant Human MD1, Fc-tag
中文名称：重组人MD1蛋白
别名：dJ80N2.1; MD-1; MD1; MMD-1
货号：NBL-250393
品牌：辰辉创聚生物®️
规格：100UG; 1MG; Bulk
| 产品描述
NebuSelect™ Recombinant Human MD1, Fc-tag(Cat#NBL-250393) is expressed in HEK293 with Fc-tag at C-terminus.
| 产品属性
Species: Human
Expression System: HEK293
Molecular Weight: 42 kDa
Target Name: MD1
Purity: >95%
Formulation: See COA
Endotoxin: ＜1EU/ug(LAL Method)
Storage: 4°C for short term; -20°C for long term.
For Research Use Only!
To get more information, please contact us freely.
郑重声明：仅用于科学研究，不可用于诊断或治疗。
更多产品细节，请联系我司相关客服人员。
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Quantification of Human IgG and Related Fc Fusion Proteins by a Human IgG/Fc Capture ELISA
of recombinant human IgGs after production and purification for further assays. Here, we describe a human IgG/Fc capture enzyme linked immunosorbent assay (ELISA) which is simple, robust, inexpensive and specific for all types of human IgGs and related Fc fusion
Construction of Recombinant Human Cytomegalovirus
genome. These studies can extend to the introduction of viral or foreign genetic material into ectopic sites in the viral genome, to investigate viral cis -control sequences or to phenotypically modify or tag the recombinant virus. Genetically modified
Assessing Fc Glycan Heterogeneity of Therapeutic Recombinant Monoclonal Antibodies Using NP-HPLC
Recombinant monoclonal antibodies (rMAbs) are becoming major human therapeutics to treat life-threatening diseases such as cancer. These rMAbs are produced using either in vitro cell culture processes or transgenic technology in animals
技术资料暂无技术资料 索取技术资料
